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Prognostic indices and therapy in 
IgA nephropathy: Toward a solution
FW Ballardie1 and RD Cowley1
IgA nephropathy is the primary renal disease with the greatest impact on 
services. The paucity of trials with high evidence-based standards gives 
emphasis to issues of the rationalization of therapies. Now that certain 
treatments are increasingly accepted and others under evaluation, 
reliable discriminatory tests are essential to define and select patients 
at high risk of progression before irreversible loss of renal tissue, while 
avoiding drug exposure in others.
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The search for prognostic determinants 
remains central, one of the most impor-
tant investigative ﬁelds in IgA nephropathy, 
the most prevalent of primary glomeru-
lopathies. The design of high-quality, 
successful, randomized controlled trials, 
of which there are few, is fundamentally, 
and in a mathematical sense, inﬂuenced 
by the homogeneity of patient cohorts.1 
When optimized, deﬁning patient variables 
within a narrow range at entry, such trials 
advantageously—and very disproportion-
ately—reduce the patient numbers required 
to achieve data of signiﬁcance and thus can 
be small, powerful tools to evaluate treat-
ment eﬃcacies in a way once considered 
insuﬃcient.1–3 There is an ethical prereq-
uisite to justify using increasingly sophis-
ticated but potentially toxic therapies early 
in the course of IgA disease, in higher-risk 
patients before major loss of glomerular ﬁl-
tration rate (GFR). Variables used to date in 
controlled trials of IgA nephropathy have 
been only clinical—heavier proteinuria or 
inexorably progressive disease2–4—perhaps 
a simplistic approach in the context of cur-
rent understanding of pathogenesis.
In the three decades since early thera-
peutic studies in IgA nephropathy were 
described, there has been progress in study 
design. Clinical assessments and pathology 
assays to deﬁne patients at higher long-
term risk have been described. Trends in 
these IgA nephropathy research topics in 
each of the last three decades show that 
the focus is on histology and urinalysis; 
the latter continues to increase rapidly, 
with genotyping having increased by the 
largest percentage in the past decade. Sero-
logical analyses are declining, with little 
change in the number of publications in 
the biochemical ﬁeld (according to a search 
of PubMed citations). The numbers of 
publications that address the prognostic 
value of tests in these ﬁelds are shown in 
Figure 1. The picture emerging is that new 
data that can be constructed solely from 
clinical and histological characteristics are 
limited. To advance IgA nephropathy treat-
ments further with succinct shorter-term 
but meaningful trials, there will continue to 
be a need for relevant and robust immuno-
pathological assays.
How do we best choose which entities to 
evaluate as a prognostic index in IgA neph-
ropathy? In any complex biological system, 
the quandary of choosing from the myriad 
of measurable variables to assess a disease, 
“some function or other, we know not 
what, in advance of examining the case,”5 
has slowed progress in making compari-
sons between, and assessing the value of, 
prognostic markers published to date in 
IgA nephropathy. Recently, in situ hybridi-
zation, immunostaining, and semiquantita-
tive polymerase chain reaction assays have 
revealed a wide array of proinﬂammatory 
cytokines, and chemokines, in both circu-
lating monocytes and lymphocytes and in 
renal biopsy tissue in IgA nephropathy in 
comparison with normal renal tissue. Most 
are upregulated in circulating cells and 
in renal tissue in disease, although there 
are exceptions: for example, transform-
ing growth factor-β, either the protein or 
its encoding mRNA, has been variously 
described as upregulated in blood mono-
cytes, but, in contrast, downregulated in 
the kidney, at least in mRNA—though not 
in protein—immunoassays. Furthermore, 
upregulation can be selective, or variable, 
according to clinical disease state, as for 
interleukin-6 versus transforming growth 
factor-β.6 
Monocyte chemotactic peptide-1/CCL-2 
is one of at least 26 CC (β) chemokines that 
constitute one of the four distinct chem-
okine classes; the term CC denotes their 
protein conformational similarity resulting 
from two adjacent cysteine residues near 
the amino terminus. In addition to mono-
cyte recruitment, MCP-1 also has a central 
proinﬂammatory role as a chemokine for 
T lymphocytes, eosinophils, and basophils. 
Polymorphisms of A2518G in the gene 
encoding MCP-1 and consequential vari-
ation in the protein gene product have been 
described in an IgA nephropathy patient 
population.7 Macrophages mediate injury 
through several mechanisms: the genera-
tion of radical oxygen species and nitric 
oxide, complement species, and proinﬂam-
matory cytokines. They aﬀect supporting 
matrix and vasculature through the expres-
sion of metalloproteinases and vasoactive 
peptides and enhance the transdiﬀerentia-
tion of tubular epithelial cells into intersti-
tial ﬁbroblasts, contributing to scarring. 
Although MCP-1 is an attractive candidate 
for assay, the ostensibly daunting task of 
deciding the optimal cytokine or chemo-
tactic protein(s) to define higher-risk 
IgA disease patients remains. Histology 
and biopsy grading has, however, shown 
consensus on interstitial ﬁbrosis, tubular 
atrophy, and scarring as an adverse prog-
nostic indicator, and MCP-1 is expressed in 
abundance in diseased renal tissues.8 Fur-
thermore, across a spectrum of glomeru-
lopathies, there is a close correlation 
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between, on the one hand, albuminuria, 
urinary MCP-1, and interstitial macro-
phage inﬁltration with in situ histologi-
cal damage, and on the other hand, the 
pivotal clinical outcome of renal survival.9 
The intriguing proposal based on these 
data is that albuminuria, and other serum 
or glomerular-sourced proteins within 
the 40- to 100-kilodalton size range, pos-
sibly including transferrin,9 might trigger 
MCP-1 expression in the kidney, leading 
to monocyte inﬁltration and thus in situ 
macrophages. This reinforces the increas-
ingly held belief that the degree of albu-
minuria per se is an independent, adverse, 
risk factor for scarring and progression in 
many renal diseases. Thus, MCP-1, as well 
as proﬁbrotic cytokines, is an attractive 
candidate for urine assay as a prognostic 
variable, circumventing at least some of 
these expressed uncertainties.5
Of similar interest, but also potentially 
a marker of renal-cell repair, is epidermal 
growth factor (EGF), which plays a ubiq-
uitous role in regeneration of cell systems 
and is known to accelerate recovery from 
acute renal injury. EGF mRNA, protein, 
and cell-surface receptor (EGF-R) are 
expressed in normal kidney, localizing 
to tubule profiles, dominantly in the 
ascending limb of the loop of Henle, 
with receptor also sited in glomerular 
and capillary endothelial cells.10 Upreg-
ulation of EGF protein and encoding 
mRNA characterizes acute interstitial 
injury, whereas, in IgA nephropathy, 
expression is downregulated.11
A study developed from the research 
program of Schena and colleagues12 
(this issue) now shows that urinary EGF/ 
MCP-1 concentration ratio, measured at 
renal biopsy, is an independent risk factor 
for IgA disease progression. Furthermore, 
for practical applications of assay of the 
ratio, the timing of urinalysis was not crit-
ical; the authors demonstrated a remark-
able stability in the EGF/MCP-1 pattern 
over short time periods, although this 
was not clearly delineated into nephritic 
versus inactive disease phases. Urinaly-
sis for single inflammatory cytokines 
or chemokines is not novel,13 nor are 
ratios of these urine-excreted mediators, 
which have previously included MCP-1, 
interleukin-8, and monocyte chemotac-
tic activator.14 What distinguishes this 
elegant new study are its rationale in 
an immunopathological sense, and the 
soundness of its mathematical analysis.
Ratios of urinary EGF/MCP-1 were 
chosen with the intention of improving 
sensitivity and speciﬁcity of tests in rela-
tion to a clinical outcome variable, and 
this was achieved in comparison with 
either chemokine alone, or its standardi-
zation against urine creatinine—proof, 
indeed, that careful study design and 
mathematical appraisal can enhance the 
discriminatory power of immunopatho-
logical assays. Predictive parameter val-
ues, within the EGF/MCP-1 ratio variable, 
were determined with the use of receiver 
operating characteristic curve integra-
tion areas, a long-established means of 
improving the information extractable 
from a given set of data in comparison 
with the test from which its principles are 
derived—in this case, the more familiar 
Mann-Whitney U test. Receiver operat-
ing characteristic curve integration, and 
multivariate analysis, allowed prediction 
of renal survival in this study into tertiles 
that described prognosis, the probability 
of progressing to end-stage renal failure. 
The study does make some assumptions 
in its design—for example, that EGF 
and MCP-1, when analyzed as a ratio, 
and not each standardized against urine 
creatinine, hold constant their clearance 
relationship to the common factor of urine 
creatinine across a range of potentially 
declining GFRs. Given that EGF and 
MCP-1 have broadly similar molecular 
weights, and sizes (13.4 and 11.04 kilodal-
tons, respectively), this assumption may 
be a reasonable one. Notwithstanding this 
uncertainty, and other physicochemical 
diﬀerences—for example, pI/net protein 
charge, which is likely to affect relative 
clearances through the glomerular base-
ment membrane with diﬀerent GFRs—the 
study data as analyzed remain robust.
The conclusions from the data of Schena 
and colleagues12 should prove important 
in patient management. IgA nephropathy 
patients at higher risk are currently iden-
tiﬁable as those with heavier proteinuria 
or are already inexorably progressing. 
Urinary EGF/MCP-1 ratios may further 
improve discrimination, earlier in the 
disease course, of which patients should 
be oﬀered one or more of the range of 
current or future treatment regimens 
(reviewed by Ballardie1,15). The objec-
tive in this approach would be to prevent 
the ensuing and irreversible problems of 
glomerular loss, hypertension, and, ulti-
mately, hyperﬁltration, when no therapy 
may be successful. Such an approach may 
also be useful in planning studies evalu-
ating novel treatments for IgA nephropa-
thy, deﬁning patient cohorts with better 
homogeneity, and enabling more succinct 
trials. This follows from calculation of 
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Figure 1 | IgA nephropathy: trends in original research publication subject matter for each 
decade to 2007. Numbers in each genre are those addressing prognosis or renal survival.
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numbers required to achieve signiﬁcance 
in a controlled trial, which increase with 
the mathematical factor: reciprocal of 
the data spread, squared1,15—applied to 
whichever variable is being assessed in 
a trial, for example, estimated GFR, or 
rate of loss of estimated GFR. In practice, 
this means that study patient numbers 
rise more than exponentially.1,15 Schena 
and colleagues’ study analysis12 assessed 
both of the latter variables in relation to 
urinary EGF/MCP-1. Doubtless, other, 
improved indices will be discovered, but 
urinary EGF/MCP-1 may be the best cur-
rent assay available as a prognostic tool to 
complement clinical characteristics in IgA 
nephropathy (Figure 1).
The value of intensive mathemati-
cal analysis of data in collaboration with 
dedicated clinical statisticians is also clearly 
evident in this study.12 This approach 
is increasingly being invoked in related 
fields and may become essential with a 
disease as heterogenous and ﬁckle as IgA 
nephropathy, to achieve robust and mean-
ingful analysis of smaller patient cohorts, 
a principle used in one recent study on 
prognostic indices with little more than 20 
patients,16 and in another with fewer than 
40 patients.3 Adoption of methodology 
with rigorous and contemporary math-
ematical frameworking in clinical studies 
of IgA nephropathy is likely to become the 
norm rather than the exception, thus accel-
erating research progress. The next decade 
of the 21st century is anticipated as an excit-
ing and productive time, with the prospect 
of rapid progress in our understanding of 
the pathogenesis and optimal treatments of 
IgA nephropathy.
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Calcium, cyclic AMP, and MAP 
kinases: Dysregulation in 
polycystic kidney disease
BD Cowley Jr.1
Low intracellular calcium, present in untreated polycystic kidney 
epithelia, results in a proliferative response to cyclic adenosine 
monophosphate. Treatment with a calcium channel blocker (CCB) 
caused exacerbation of autosomal dominant polycystic kidney disease 
in rats. Data regarding use of CCBs in human polycystic kidney disease 
(PKD) are limited and mixed. Thus, it is premature to extrapolate these 
findings to human PKD.
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Cyst development in polycystic kidney 
disease (PKD) requires epithelial-cell 
proliferation, ﬂuid secretion into closed 
cyst cavities, and extracellular matrix 
remodeling. Abnormal proliferation and 
ﬂuid secretion in PKD are at least partially 
mediated by intracellular cyclic adenosine 
monophosphate (cAMP). Autosomal 
dominant PKD (ADPKD) is associated 
with a phenotypic change in the epithelial 
cellular response to intracellular cAMP. 
In normal renal epithelial cells, cAMP 
is antiproliferative; however, in ADPKD 
epithelial cells, cAMP is pro-prolifera-
tive. This phenotypic change appears to be 
associated with decreases in intracellular 
calcium (Ca2+) with a resultant change in 
intracellular signaling through mitogen-
activated protein (MAP) kinase pathways 
(Figure 1). Speciﬁcally, in normal renal 
epithelia, increased intracellular cAMP 
results in inhibition of Raf-1/MAP kinase 
kinase/extracellular signal-regulated 
kinase (Raf-1/MEK/ERK) and is thus 
